This page shows the latest HIF-PHI news and features for those working in and with pharma, biotech and healthcare.
Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). In contrast to ESAs, HIF-PIH inhibitors stimulate endogenous production of erythropoietin, the protein on which ESAs are based.
Daprodustat – a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) – will be distributed in Japan by Kyowa Kirin if it gets the nod from the Ministry of Health, Labour and Welfare ... In contrast, HIF-PHI drugs stimulate endogenous
Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) and according to AZ’s chief medical officer Sean Bohen is the first oral drug in this class, as well ... In contrast, HIF-PH inhibitors stimulate endogenous production
CKD) . The orally-active hypoxia-inducible prolyl hydroxylase inhibitor (HIF-PHI) could be a $450m product by 2020, according to Credit Suisse forecasts, and is one of a block of new ... administration.". GSK is in a race to market with other HIF-PHI
The drug is an orally administered small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHI) and offers an alternative to injectable treatments based on erythropoietin (EPO), which account for
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...